ABVC BioPharma, Inc. (ABVC)
0.8444
-0.08
(-8.22%)
USD |
NASDAQ |
Aug 24, 16:00
0.8444
0.00 (0.00%)
After-Hours: 20:00
ABVC BioPharma Enterprise Value : 28.48M for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 28.48M |
| August 20, 2026 | 28.48M |
| August 19, 2026 | 29.72M |
| August 18, 2026 | 27.85M |
| August 17, 2026 | 27.42M |
| August 14, 2026 | 28.75M |
| August 13, 2026 | 30.33M |
| August 12, 2026 | 30.35M |
| August 11, 2026 | 31.02M |
| August 10, 2026 | 30.09M |
| August 07, 2026 | 31.95M |
| August 06, 2026 | 31.95M |
| August 05, 2026 | 31.68M |
| August 04, 2026 | 33.28M |
| August 03, 2026 | 32.48M |
| July 31, 2026 | 31.68M |
| July 30, 2026 | 33.55M |
| July 29, 2026 | 31.68M |
| July 28, 2026 | 33.01M |
| July 27, 2026 | 31.95M |
| July 24, 2026 | 35.41M |
| July 23, 2026 | 36.74M |
| July 22, 2026 | 36.21M |
| July 21, 2026 | 37.54M |
| July 20, 2026 | 36.74M |
| Date | Value |
|---|---|
| July 17, 2026 | 38.07M |
| July 16, 2026 | 37.01M |
| July 15, 2026 | 38.87M |
| July 14, 2026 | 40.47M |
| July 13, 2026 | 40.74M |
| July 10, 2026 | 45.00M |
| July 09, 2026 | 43.40M |
| July 08, 2026 | 58.59M |
| July 07, 2026 | 58.59M |
| July 06, 2026 | 55.39M |
| July 02, 2026 | 52.73M |
| July 01, 2026 | 51.93M |
| June 30, 2026 | 46.87M |
| June 29, 2026 | 46.41M |
| June 26, 2026 | 45.34M |
| June 25, 2026 | 43.21M |
| June 24, 2026 | 40.01M |
| June 23, 2026 | 39.48M |
| June 22, 2026 | 39.75M |
| June 18, 2026 | 40.55M |
| June 17, 2026 | 40.81M |
| June 16, 2026 | 38.95M |
| June 15, 2026 | 38.15M |
| June 12, 2026 | 36.29M |
| June 11, 2026 | 39.48M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Anika Therapeutics, Inc. | 278.32M |
| Perspective Therapeutics, Inc. | 143.57M |
| MiMedx Group, Inc. | 512.35M |
| Abbott Laboratories | 229.49B |
| AngioDynamics, Inc. | 613.87M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.8105M |
| Total Expenses (Quarterly) | 0.7369M |
| EPS Diluted (Quarterly) | -0.0283 |
| Earnings Yield | -34.08% |
| Normalized Earnings Yield | -31.43 |